Horizon scanning in oncology

Duration: since Oktober 2009; new concept from 2025 (9.7 PM)

Subject:
Early assessments of new oncologicals have been carried out since 2009 to support decision-making by (regional) drug commissions and payers. As part of the HSO project, early assessments (n=91) of selected new oncologicals were prepared by the end of 2019, for which significant financial and/or therapeutic consequences were predicted.  Due to the changing European environment, fact sheets on all new drug-based cancer therapies have been prepared monthly since 2020 (n=190) and categorised using the ESMO scale (magnitude of clinical benefit/MCBS). From 2025, all new oncology drugs will be assessed in European cooperation as part of the HTA regulation and the assessments will be available just 1-2 months after authorisation.

For this reason, the existing  programme line will be changed:

Method:

• Contextualisation of the European HTAs on oncologicals
• Advance planning of the notified oncologicals for budgeting

Timetable: January to December 2025